Back to Authors

Palmisano, N.

A5032700328 | I2799360765

Mayo Clinic

Thomas Jefferson University Hospital

Citations 3

EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 123-124

10.1002/hon.83_2629

Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 7538-7538

10.1200/jco.2018.36.15_suppl.7538

SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG‐ACRIN CANCER RESEARCH GROUP (E4412)

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 84-85

10.1002/hon.2437_72